Project Grant HT94252510449

The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $702,748 to Weill Medical College of Cornell University to research the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer immunotherapies. The key objectives are to: 1) characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, 2) identify the clinically...

This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under CFDA Program 93.394 - Cancer Detection and Diagnosis Research, provides $1,453,091 in funding to develop and clinically evaluate an imaging-enabled, adaptable CAR T cell (IMAC) therapy platform. The University of Pennsylvania will lead this project, which aims to create a novel CAR T cell approach that can be monitored and controlled through PET imaging and targeted biologics. The goal is to enable safe and...

The federal Project Grant award R01CA289387, totaling $657,121.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to develop a novel dendritic cell therapy for treating leptomeningeal disease (LMD), a severe complication that occurs in 5% of advanced-stage breast cancer patients. The research aims to...

This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $672,844 supports research to determine the effectiveness of a monoclonal antibody (B10G5) in activating natural killer (NK) cells and reshaping the tumor microenvironment to improve adoptive NK cell therapy for canine soft tissue sarcomas. The research, conducted by Northwestern University, aims to: 1) evaluate the safe and effective dose of B10G5 in activating endogenous NK cells...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...

The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...

This federal Project Grant award of $636,222 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of Pittsburgh to investigate how immune checkpoint inhibitor-associated gut bacteria can modulate tumor immunity and enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in melanoma. The key goals of the research are to: 1) Determine whether ICI-associated bacteria metabolize dietary tryptophan into aryl...